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Abstract
Sudden unexplained death (SUD) takes up a considerable part in overall sudden death cases, especially in adolescents and 
young adults. During the past decade, many channelopathy- and cardiomyopathy-associated single nucleotide variants (SNVs) 
have been identified in SUD studies by means of postmortem molecular autopsy, yet the number of cases that remain incon-
clusive is still high. Recent studies had suggested that structural variants (SVs) might play an important role in SUD, but there 
is no consensus on the impact of SVs on inherited cardiac diseases. In this study, we searched for potentially pathogenic SVs 
in 244 genes associated with cardiac diseases. Whole-exome sequencing and appropriate data analysis were performed in 
45 SUD cases. Re-analysis of the exome data according to the current ACMG guidelines identified 14 pathogenic or likely 
pathogenic variants in 10 (22.2%) out of the 45 SUD cases, whereof 2 (4.4%) individuals had variants with likely functional 
effects in the channelopathy-associated genes SCN5A and TRDN and 1 (2.2%) individual in the cardiomyopathy-associated 
gene DTNA. In addition, 18 structural variants (SVs) were identified in 15 out of the 45 individuals. Two SVs with likely 
functional impairment were found in the coding regions of PDSS2 and TRPM4 in 2 SUD cases (4.4%). Both were identified 
as heterozygous deletions, which were confirmed by multiplex ligation-dependent probe amplification. In conclusion, our 
findings support that SVs could contribute to the pathology of the sudden death event in some of the cases and therefore 
should be investigated on a routine basis in suspected SUD cases.
Keywords Forensics · Massively parallel sequencing (MPS) · Exome sequencing · Single nucleotide variant (SNV) · 
Structural variants (SV) · Copy number variation (CNV)
Introduction
Sudden death events in young individuals often represent 
the first manifestation of an undetected genetic disease, 
which remained without any symptoms during lifetime. 
Although some of the deceased show cardiac structural 
abnormalities and can be explained by autopsy, approxi-
mately 30% of sudden death cases still remain elusive and 
are therefore termed as sudden unexplained death (SUD) 
[1, 2]. In the past years, postmortem molecular autopsy 
enabled the identification of hidden cardiac diseases in a 
series of SUD cases. These diseases include mainly chan-
nelopathies or cardiomyopathies associated with single 
nucleotide variants (SNVs) located in the coding regions of 
functional genes [3–6]. In addition, some variants located in 
noncoding regions, such as regulatory elements and splice 
sites, might be accountable for serious functional effects 
[7–10]. Recent studies revealed that structural variants 
(SVs), including copy number variations (CNVs), might 
play an important role in SUD and could explain some of 
the unresolved cases [11–14].
SVs include diverse genomic alterations like deletions, 
duplications, insertions, inversions, translocations, or com-
plex rearrangements of relatively large segments such as 
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tandem exon duplications, or complex gains or losses of 
homologues sequences at multiple sites in the genome, com-
monly referred to as CNVs [15, 16]. While SVs are consider-
ably less common than SNVs, they have greater functional 
potential due to their larger size, and they are more likely to 
alter gene structure [17]. SVs and CNVs can influence gene 
expression, phenotypic variation, and adaptation, by disrupt-
ing genes and altering gene dosage. Many SVs are described 
to confer risk to complex disease traits or increase disease 
susceptibility to e.g. HIV-1 infection [18] or neurodevel-
opmental disorders including autism [19], schizophrenia 
[20], and depression [21]. Besides, pathogenic CNVs have 
been reported in cardiac diseases such as Brugada syndrome 
(BrS) [11], arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) [12], or sudden cardiac death (SCD)-related 
cases [13, 14]. One previous study examined CNVs in a 
large cohort of SUD cases and patients that had an inherited 
cardiac disease and discovered that the frequency of identi-
fied CNVs varied from 1.4 to 5.1% among cases with dif-
ferent underlying diseases [22]. Another study investigated 
a small cohort of 13 sudden arrhythmic death syndrome 
(SADS) and sudden unexplained death in infancy (SUDI) 
cases with whole genome sequencing and whole transcrip-
tome sequencing. However, they did not find any SVs in the 
coding and regulatory regions of 100 cardiac genes [23]. A 
recent study focused on 2 large Amish families with multiple 
sudden deaths and sudden cardiac arrests in young individu-
als and identified a homozygous multi-exon duplication in 
RYR2 [24]. Another study investigated a Tunisian family 
with high incidence of SCD in young family members, but 
did not find any pathological relevant CNVs [25]. The lack 
of a consensus of the impact of SVs on inherited cardiac dis-
eases emphasized the need of more evidence on this topic.
The aim of this study was to screen for potentially patho-
genic SVs in 244 genes associated with cardiac diseases in a 
cohort of 45 SUD cases. Whole-exome sequencing (WES) in 
35 out of these 45 cases has already been performed earlier 
[4], whereas 10 additional SUD cases were analyzed as part 
of this study. Due to updates in the recommendations for 
rare variant classification, the exome sequencing data of all 
45 SUD cases was analyzed and classified according to the 
current ACMG guidelines [26].
Materials and methods
SUD cohort
All SUD cases had been autopsied at the Zurich Institute of 
Forensic Medicine (ZIFM) in Switzerland between 2012 and 
2019. The sudden death victims were examined according to 
the respective European and Swiss guidelines for the man-
agement of young SUD cases [27–29], including a thorough 
death scene investigation, a complete autopsy with pharma-
cological-toxicological and histopathological screening, and 
a review of the clinical history. The SUD cohort consisted 
of 45 cases with a mean age of 30.2 ± 14.5 years (range: 
1–63 years of age) (Table S1). Seventy-five percent of the 
deceased were males and most of them were of European 
origin (89%). Another 5 cases (11.1%) were of African (3 
cases), Indian (1 case), and Chinese (1 case) origin. Exome 
sequencing data was already available for 35 of the SUD 
cases [4]. Additional 10 SUD cases were analyzed according 
to the workflow described in our previous study [4].
Exome sequencing and bioinformatics
Genomic DNA of the 10 new SUD cases was obtained from 
shock-frozen kidney tissue. DNA extraction was performed 
using the QIAamp DNA Mini Kit (Qiagen, Hombrechtikon, 
Switzerland) according to the manufacturer’s protocol. DNA 
quantities were determined with a Quantus™ Fluorometer 
(Promega, Dübendorf, Switzerland). The  SureSelectXT tar-
get enrichment and  SureSelectXT All Exon V5 + UTR kits 
(Agilent Technologies AG, Basel, Switzerland) were used 
for DNA library preparation and exome capture, followed by 
quality and quantity assessment with the TapeStation system 
using DNA 1000 ScreenTapes (Agilent Technologies AG). 
DNA libraries were sequenced on an Illumina NovaSeq 6000 
instrument (Illumina Inc., San Diego, CA, USA) with 150 
paired-end reads and a mean coverage of 65 × per sample. 
Sequences were aligned to the reference genome (GRCh37/
hg19) using BWA [30] and samples were required to have at 
least 80% of the exome covered at ≥ 20 × read depth. Variant 
discovery was performed by means of GATK [31], following 
the GATK best practice workflow [32].
SNV identification
Data analysis was confined to a target gene panel consisting 
of 244 genes associated with cardiac diseases (Table S2). 
The annotation of the VCF files was performed with the 
software Alamut Batch, version 1.11 (Interactive Biosoft-
ware, Rouen, France) and the visualization of the coverage 
of SNVs was done with the software IGV, version 2.4.16 
[33]. SNV screening was performed according to an updated 
version of our previously published in-house filtering strat-
egy [4] and to the ACMG standards and guidelines for the 
interpretation of sequence variants [26]. Our filter strategy 
selects SNVs with a stringent global minor allele frequency 
value (MAF) of less than or equal to 0.005% derived from 
the genome aggregation database (gnomAD) which is the 
largest available human database, including 125,748 exomes 
and 15,708 whole genomes from unrelated individuals of 
different ethnicities, sequenced as part of various population 
genetic studies [34]. In addition, synonymous and intronic 
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variants were excluded, focusing only on exonic and splice 
site SNVs. Pathogenicity of the SNVs was assigned based 
on the evaluation of variant types (null variants, frameshift 
variants, splice site variants, or missense variants) and on 
the genome interpretation database VarSome [35]. Identi-
fied SNVs have been submitted to the Leiden Open Varia-
tion Database (Individuals Nr. 00,315,499–00,315,504 and 
00,324,655–00,324,658) (http:// datab ases. lovd. nl).
SV identification
SVs were called using LUMPY [15]. Briefly, discordant 
paired-end alignments were retrieved using samtools [36] 
(samtools view -b -F 1294) and the split-read alignments 
were extracted using the LUMPY auxiliary script extract-
SplitReads_BwaMem. The discordant paired-end and the 
split-read file were then parsed, together with the align-
ment (bam) file to lumpyexpress with default settings. The 
resulting VCF files were annotated using ANNOVAR [37] 
using the UCSC human genome version GRCh37/hg19 as 
reference and the Database of Genomic Variants (DGV) 
as variants database [38]. Among the SVs within our tar-
get genes, those identified in more than one sample were 
excluded from subsequent analysis, since pathogenic SVs 
that contribute to SUD should be rare variants according to 
the ACMG guidelines [26]. Furthermore, SVs longer than 
1 Mbp were excluded because in these cases, the expression 
levels of too many genes were considered abnormal, which 
makes them difficult to validate. The remaining SVs were 
manually checked using the IGV software; only those with 
a characteristic gene expression alteration were considered 
eligible SV candidates. Allele frequencies of the candidate 
SVs were checked in the gnomAD-SV database [45].
MLPA validation
The identified candidate SVs were confirmed by multiplex 
ligation-dependent probe amplification (MLPA) according 
to the manufacturer’s instructions. Self-designed oligos 
for the detection of our target regions were synthesized by 
Microsynth (Microsynth AG, Balgach, Switzerland). In 
brief, 100 ng of DNA and a customized probemix consist-
ing of synthetic oligos (Table S3) and the P200 reference 
probemix (MRC Holland, Amsterdam, Netherlands) were 
used in the hybridization reaction. Fragment separation was 
performed on a 3130xl Genetic Analyzer (Thermo Fisher 
Scientific, Reinach, Switzerland). Fragment analysis and 
comparative analysis results were generated using Coffa-
lyser.Net software (MRC Holland).
Results
SNV identification
Following the current ACMG guidelines for variant interpre-
tation [26], 14 pathogenic or likely pathogenic SNVs were 
identified in 10 (22.2%) out of the 45 SUD cases (Table 1 
and Table S4). These variants were located in genes that 
are linked to cardiomyopathies (1 SUD case), ion chan-
nelopathies (2 SUD cases), connective tissue diseases and/
or congenital malformation syndromes (3 SUD cases), and 
metabolic diseases (4 SUD cases). Out of these 14 SNVs, 
2 heterozygous stop-gain variants (DTNA, NM_001390.4, 
c.2224C > T, p.(Gln742*) and LZTR1, NM_006767.4, 
c.2440C > T, p.(Gln814*)), 1 heterozygous two-base duplica-
tion (CALR3, NM_145046.4, c.387dup, p.(Ile130Tyrfs*11)), 
1 homozygous one-base deletion (LZTR1, NM_006767.4, 
c.604_605del, p.(Met202Valfs*57)), and 1 heterozy-
gous missense variant (SCN5A, NM_001099404.1, 
c.2204C > A, p.(Ala735Glu)) were predicted as pathogenic. 
In addition, 2 heterozygous stop-gain variants (ALMS1, 
ENST00000264448.6, c.54_55insTAG, p.(Glu19*) and 
MLYCD, NM_012213.3, c.1073C > A, p.(Ser358*)), 2 
heterozygous deletions (SLC37A4, ENST00000357590.5, 
c.528del, p.(Val177Trpfs*35) and TRDN, NM_006073.4, 
c.1923_1924del, p.(Leu643Serfs*19)), and 5 heterozygous 
missense variants (ACADS, NM_000017.4, c.320G > A, 
Table 1  Pathogenic or likely pathogenic SNVs identified in our SUD cohort
Case rs-Nr. Gene HGVS genomic RefSeq-Nr. HGVS RefSeq-Nr. Coding effect cDNA Protein change MAF (gnomAD
44
) Pathogenicity ACMG categories
26 Coverage Heterozygous allele frequency Associated diseases
SUDS008 rs137854611 SCN5A Chr3(GRCh37):g.38639278G>T NM_001099404.1 missense c.2204C>A p.(Ala735Glu) 0.0000040140 pathogenic PS3, PM1, PM2, PM5, PP2, PP3, PP5 61 0.46 BrS, LQTS
SUDS028 rs776788495 LZTR1 Chr22(GRCh37):g.21343924_21343925del NM_006767.4 frameshift c.604_605del p.(Met202Valfs*57) 0.0000279100 pathogenic PVS1, PM2, PP3 37 0.47 Noonan syndrome
SUDS030 . SLC37A4 Chr11(GRCh37):g.118898435del ENST00000357590.5 frameshift c.528del p.(Val177Trpfs*35) 0.0000000000 likely pathogenic PVS1, PM2, PP3 91 homozygous Glycogen storage disease 
SUDS038 rs755697930 ACADS Chr12(GRCh37):g.121174898G>A NM_000017.4 missense c.320G>A p.(Arg107His) 0.0000363100 likely pathogenic PM1, PM2, PM5, PP2, PP3 56 0.48 Acyl-CoA dehydrogenase deficiency
SUDS051 rs539219309 ACADS Chr12(GRCh37):g.121176354C>T NM_000017.4 missense c.814C>T p.(Arg272Cys) 0.0000322600 likely pathogenic PM1, PM2, PP2, PP3 77 0.49 Acyl-CoA dehydrogenase deficiency
SUDS059 . DTNA Chr18(GRCh37):g.32464701C>T NM_001390.4 stop gain c.2224C>T p.(Gln742*) 0.0000000000 pathogenic PVS1, PM2, PP3 562 0.44 LVNC
SUDS066 . ALMS1 Chr2(GRCh37):g.73613050_73613051insTAG ENST00000264448.6 stop gain c.54_55insTAG p.(Glu19*) 0.0000000000 likely pathogenic PVS1, PM2 31 0.38 Alstrom syndrome
SUDS066 . SOS1 Chr2(GRCh37):g.39233616C>A NM_005633.3 missense c.2728G>T p.(Asp910Tyr) 0.0000000000 likely pathogenic PM1, PM2, PP2, PP3 45 0.41 Noonan syndrome
SUDS066 . FBN2 Chr5(GRCh37):g.127674660T>C NM_001999.4 missense c.3437A>G p.(Tyr1146Cys) 0.0000000000 likely pathogenic PM1, PM2, PP3, PP5 193 0.48 Marfan syndrome
SUDS075 rs1392689787 LZTR1 Chr22(GRCh37):g.21351554C>T NM_006767.4 stop gain c.2440C>T p.(Gln814*) 0.0000000000 pathogenic PVS1, PM2, PP3 180 0.42 Noonan syndrome 
SUDS084 rs781420323 TRDN Chr6(GRCh37):g.123576253_123576254del NM_006073.4 frameshift c.1923_1924del p.(Leu643Serfs*19) 0.0000300600 likely pathogenic PVS1, PM2, PP5 23 0.43 CPVT
SUDS112 . CALR3 Chr19(GRCh37):g.16601188dup NM_145046.4 frameshift c.387dup p.(Ile130Tyrfs*11) 0.0000000000 pathogenic PVS1, PM2, PP3 98 0.45 Familial HCM, ARVC
SUDS112 . MLYCD Chr16(GRCh37):g.83948685C>A NM_012213.3 stop gain c.1073C>A p.(Ser358*) 0.0000000000 likely pathogenic PVS1, PM2, BP4 112 0.48 MLYCD deficiency 
SUDS112 . ANK2 Chr4(GRCh37):g.114264208C>G NM_001148.5 missense c.4158C>G p.(Phe1386Leu) 0.0000000000 likely pathogenic PM1, PM2, PP2, PP3 51 0.41 LQTS, CPVT
ACMG American College of Medical Genetics and Genomics recommendations, ARVC arrhythmogenic right ventricular cardiomyopathy, BrS 
Brugada syndrome, CPVT catecholaminergic polymorphic ventricular tachycardia, gnomAD genome aggregation database, HCM hypertrophic 
cardiomyopathy, LQTS long QT syndrome, LVNC left ventricular non-compaction cardiomyopathy, NA not available
Color description for ACMG categories: red = very strong and strong evidence of pathogenicity, orange = moderate and supporting evidence of 
pathogenicity, green = supporting evidence of benign impact
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p.(Arg107His);  ACADS, NM_000017.4, c.814C > T, 
p.(Arg272Cys); SOS1, NM_005633.3, c.2728G > T, 
p.(Asp910Tyr); FBN2, NM_001999.4, c.3437A > G, 
p.(Tyr1146Cys) and ANK2, NM_001148.5, c.4158C > G, 
p.(Phe1386Leu)) were predicted as likely pathogenic.
In general, the re-analysis and re-classification of our 
recently published exome data of the 35 SUD cases [4] 
caused a change in the classification of the pathogenicity 
in the previously reported 11 variants (Table S5). Six of 
the 11 previously reported variants in the genes ACAD9 
(p.(Arg420Cys)), AKAP9 (p.(Asn2045Ser)), FBN2 
(p.(Gln2432His)), MYLK (p.(Arg1250His)), SEMA3A 
(p.(Arg66Trp)), and RYR2 (p.(Glu1127Gly)) had a MAF 
greater than 0.005% and were therefore filtered out. The 
pathogenicity of the remaining 5 variants were down-clas-
sified from probably pathogenic (BMPR2 (p.(Pro864Leu)) 
and KCN5E (p.(Tyr62Asn))) or likely pathogenic (EFEMP2 
(p.(Arg185His)), RYR2 (p.(Ala3814Val)), and RYR2 
(p.(Gln4164Glu)) to uncertain significance (Table S5).
SV identification
After pre-screening and IGV check, a total of 18 SVs were 
identified in 15 out of the 45 SUD cases (Table 2), located in 
17 different genes (ABCC9, CDH2, DMPK, DPP6, EFEMP2, 
FXN, GPD1L, KCNJ2, LAMA4, NOS1AP, PDLIM3, PDSS2, 
PPA2, PRKAG2, PRKG1, PTPN11, TRPM4). The lengths of 
these SVs varied from 35 to 6079 bp, and most of them were 
positioned in the intergenic or intronic regions of our target 
genes. Out of these 18 SVs, the most promising 2 were het-
erozygous deletions located in the coding regions of PDSS2 
and TRPM4, respectively (Fig. S1).
The 71-bp deletion of PDSS2 (NM_020381.4: c.1009-
4103_1009-4033del), which can only be identified in exon 
3 of one gene isoform (transcript ID: ENST00000449027), 
Table 2  SVs identified in our SUD cohort
ABS absolute value, DEL deletion, SV structural variant, MAF minor allele frequency, NA pathogenicity not available in the human genomics 
database VarSome









SUDS021 EFEMP2 chr11 65,642,111 65,643,519 DEL 1408 Intergenic 0.5326 NA




SUDS028 GPD1L chr3 32,102,052 32,107,883 DEL 5831 Intergenic 0.4791 NA




SUDS030 PDLIM3 chr4 186,441,637 186,444,073 DEL 2436 Intronic in all gene 
isoforms
0.0000 NA
SUDS033 KCNJ2 chr17 68,455,097 68,461,176 DEL 6079 Intergenic 0.0000 NA




















SUDS075 TRPM4 chr19 49,686,029 49,686,064 DEL 35 Exonic in all gene 
isoforms
0.0000 Pathogenic




SUDS077 CDH2 chr18 27,629,690 27,630,006 DEL 316 Intergenic 0.5876 Uncertain signifi-
cance
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was predicted to be a variant with uncertain significance. 
This SV was identified in an 11-year-old previously healthy 
girl, who was swimming in the lake when she suddenly 
disappeared in the water. A lifeguard observed the incident 
and rescued her and immediately started resuscitation. The 
emergency team diagnosed a ventricular fibrillation and she 
became defibrillated for a single event. In the children’s hos-
pital, she had a serious derailment of the acid–base balance 
and the sugar metabolism and died shortly after. According 
to the forensic investigations, the girl was already uncon-
scious when she disappeared under water. Histological 
examination of the heart tissue revealed pre-existing changes 
in the excitation conduction system of the heart in the area 
of the secondary pacemaker center of the heart, which could 
have triggered cardiac arrhythmia and unconsciousness lead-
ing to a cardiovascular arrest.
The 35-bp deletion in exon 11 (transcript ID: 
ENST00000252826) of TRPM4  (NM_017636.4: 
c.1459_1494del, p.(Lys487_Leu498del)) was predicted as 
pathogenic. This SV was detected in a 38-year-old male. 
He complained of discomfort after drinking some alcohol 
and was found dead some hours later in his bed. He did not 
have any medical history; however, his wife reported that he 
felt unusually tired and exhausted in the last 2 months prior 
to death. Autopsy investigation revealed an enlarged heart 
(520 g, 56% enlarged according to Zeek [40]) with thicken-
ing of the heart chamber wall muscle.
MLPA validation
MLPA validation was performed on the 2 most promising 
SVs in the coding regions of PDSS2 and TRPM4, respec-
tively. According to the comparative analysis results of Cof-
falyser.Net, both SVs were confirmed to be heterozygous 
deletions (Fig. 1).
Discussion
Sudden unexplained death (SUD) takes up a considerable 
part in overall sudden death cases, especially in adolescents 
and young adults. During the past decade, many channelopa-
thy- and cardiomyopathy-associated SNVs have been iden-
tified in SUD studies by means of postmortem molecular 
autopsy [3–6], yet the number of cases that remain incon-
clusive is still high. The aim of this study was to re-analyze 
the exome data of 45 SUD cases according to the current 
ACMG guidelines and to search for potentially pathogenic 
SNVs and SVs.
Exome sequencing data was already available for 
35 SUD cases, whereas additional 10 SUD cases were 
sequenced and analyzed for rare SNVs within the scope 
of this study. Following the current ACMG guidelines for 
variant interpretation [26], we re-analyzed and re-classified 
the SNVs in the 35 SUD cases in addition to the 10 newly 
sequenced SUD cases. A total of 14 pathogenic or likely 
pathogenic variants were identified in 10 (22.2%) of the 45 
SUD cases. Out of these 10 cases, 1 individual (2.2%) car-
ried a pathogenic variant in the cardiomyopathy-associated 
gene DTNA and 2 individuals (4.4%) carried 2 (1 pathogenic 
and 1 likely pathogenic) variants in the channelopathy-asso-
ciated genes SCN5A and TRDN, respectively. Variants in the 
alpha-dystrobrevin encoding gene DTNA have been reported 
in patients with congenital heart disease and left ventricular 
non-compaction (LVNC) [41]. The SCN5A gene encodes the 
alpha subunit of the main cardiac sodium channel  Nav1.5 
and variants in this gene have been found to be causatively 
associated with BrS, long QT syndrome, cardiac conduc-
tion system dysfunction, and dilated cardiomyopathy [42]. 
Triadin-1, encoded by TRDN, is an important component 
of the calcium release unit in the sarcoplasmic reticulum 
of cardiac myocytes and a number of variants have been 
identified in patients with catecholaminergic polymorphic 
ventricular tachycardia (CPVT) [43].
Other studies already pointed out the importance of re-
analysis of sequencing data, especially in patients with com-
plex genetic diseases, as genomic databases are continuously 
updated and adjusted based on new findings in co-segrega-
tion studies and functional analyses [44]. Accordingly, when 
comparing our previously published data and the results pre-
sented in this study, some variants were interpreted differ-
ently and some new variants popped up. These changes are 
caused by the updated candidate gene list, a more stringent 
MAF as recommend by Tester et al. [45] and the assess-
ment of pathogenicity based on the genome interpretation 
database VarSome that includes additional interpretation 
criteria, such as if the variant is located in a mutational hot 
spot and/or critical and well-established functional domain 
[35]. Nevertheless, many variants remain with uncertain 
significance emphasizing the importance of cautious inter-
pretation, especially in cases without a clear phenotype and 
a complex genetic contribution. In addition, co-segregation 
analysis and functional assays are recommended to further 
evaluate the pathogenicity of identified variants.
The focus of this study was a genetic screening for SVs 
as potential contribution to the sudden unexpected death 
event. A total of 18 SVs were identified in 15 out of the 45 
individuals, but only 2 (11.1%) were located on exons. The 2 
exonic SVs were confirmed by MLPA as heterozygous dele-
tions. The functional annotation of the 2 SVs was checked 
in several databases.
The 71-bp heterozygous deletion in PDSS2 was previ-
ously identified as nsv4140011 by whole genome sequenc-
ing (WGS) in the gnomAD structural variants study [39]. 
However, neither validation information nor clinical 
assertion has been reported for this SV. According to the 
1345International Journal of Legal Medicine (2021) 135:1341–1349
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Fig. 1  SVs confirmed by MLPA. Blue/green bars represent 95% confidence interval over the reference samples (N = 3), and dots with lines 
represent 95% confidence interval estimate for each probe. In our case, the 95% confidence intervals of a PDSS2 in SUD058 and b TRPM4 in 
SUD075 did not overlap, which suggests a heterozygous deletion
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Database of Genomic Variants (DGV) [38], the deletion type 
was only observed once within 10,847 samples. Such a low 
frequency could meet the criteria for a pathogenic SV. The 
protein encoded by PDSS2 is an enzyme that synthesizes 
the prenyl side chain of coenzyme  Q10, which is one of the 
key elements in the respiratory chain. Previous research has 
revealed that individuals with primary coenzyme  Q10 defi-
ciency could have manifestations associated with multisys-
temic diseases, including encephalopathy and hypertrophic 
cardiomyopathy [46]. Therefore, we have reason to suspect 
SVs that alter the function or expression of this gene might 
be pathogenic variants. In addition, it is noteworthy that 
a missense mutation with uncertain significance in RYR2 
(p.(Ala3814Val)) has also been found in this individual. 
However, it is not clear what the biological effects of these 
genetic variants are and whether they may have contributed 
to the cause of death in this young girl.
The other 35 bp heterozygous deletion in TRPM4 was 
reported to have conflicting interpretations of pathogenicity 
(benign, likely benign, or uncertain significance) according 
to the NCBI ClinVar database. As a calcium-activated ion 
channel encoding gene, TRPM4 had already been extensively 
studied in a series of channelopathy-related reports, and some 
uncommon missense SNVs had been identified to be likely 
pathogenic in 20 out of 248 BrS patients and in 13 out of 330 
SUD cases, respectively [47, 48]. One study had demonstrated 
in-frame deletions in individuals with cardiac conduction dis-
turbances, but the deletions co-existed with other missense 
variants, which makes it hard to determine their real func-
tional impact [49]. In our case, beside the heterozygous dele-
tion in TRPM4, a pathogenic stop variant in the gene LZTR1 
(p.(Gln814*)) was identified. Variants in LZTR1 are associ-
ated with Noonan syndrome, which is a genetic disorder that 
causes multiple congenital abnormalities and characteristic 
facial features that evolve with age [50]. Furthermore, a small 
portion of patients with Noonan syndrome were reported to 
show cardiovascular diseases, including atrial septal defects 
and hypertrophic cardiomyopathy [51].
It is worth noting that a large proportion of SVs identi-
fied in this study were located in the intergenic or intronic 
regions of our target genes and thus were of unknown sig-
nificance. The evaluation of variants in these noncoding 
regions has always been challenging as the knowledge about 
their contribution to electrophysiological dysfunction is still 
very limited. Introns are usually considered to contribute 
to the control of gene expression if regulatory regions and 
noncoding functional RNA genes are affected [52–54]. A 
recent study combined the most extensive maps of CNVs 
in human populations and discovered that intronic losses 
are the most frequent CNVs in protein-coding genes [55]. 
Therefore, the significance of SVs identified in the intronic 
regions of our target genes might need to be carefully eval-
uated by functional studies. Moreover, a recent study has 
cross-referenced human transcriptome, epigenomic, and 
chromatin datasets to find causal genetic variants in non-
coding regions that alter the functionality of transcription 
regulatory elements and target gene expression associated 
with atrial fibrillation (AF) [56]. With an improved ability 
to identify these genetic variants neglected by most previous 
studies, the pathogenic mechanism behind SUD might even-
tually be better explained by routine SNV and SV testing in 
suspected SUD cases.
There are some limitations in our current study. Since we 
only focused on 244 cardiac-related genes, variants outside 
these regions could not be identified. Besides, SVs longer 
than 1 Mbp were not included in our candidate list due to 
the difficulties in confirming the MPS result. In addition, 
functional studies would be required to further investigate 
the 2 identified SVs in PDSS2 and TRPM4 in order to verify 
their potential pathogenic role and contribution to the sud-
den death event of these 2 SUD cases. When several poten-
tial pathogenic variants are under consideration, it will be 
important to find out which of the detected variants con-
tributed most to the sudden unexpected death event. In our 
study, family members were not available for co-segregation 
analyses. This would be necessary to determine the mode of 
inheritance and to identify other family members at risk for 
sudden cardiac death.
In conclusion, our study supports that SVs in cardiac dis-
ease-associated genes might be involved in some SUD cases. 
However, the functional interpretation of pathogenic SVs is 
complex and genetic evidence should be used cautiously in 
molecular diagnosis.
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